Saturday, July 25, 2009

Stem-like cells in benign tumours

Tumor 'Stem-like Cells' Exist In Benign Tumors, ScienceDaily, July 22, 2009. First paragraph:
Cancer stem-like cells have been implicated in the genesis of a variety of malignant cancers. Research scientists at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have isolated stem-like cells in benign (pituitary) tumors and used these "mother" cells to generate new tumors in laboratory mice. Targeting the cells of origin is seen as a possible strategy in the fight against malignant and benign tumors.
Based on the publication: Isolation of tumour stem-like cells from benign tumours by Qijin Xu and 10 co-authors, including John S Yu, Br J Cancer 2009(Jul 21); 101(2): 303-11 [Epub 2009(Jun 30)]. Final section of PubMed Abstract:
CONCLUSION: This study for the first time indicates that stem-like cells are present in benign tumours. The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

Friday, July 24, 2009

Translation of knowledge about CSC into clinical use

Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating Stem Cell Hypotheses into Clinical Trials. Authors: Wendy A Woodward, Robert G Bristow, Michael F Clarke, Robert P Coppes, Massimo Cristofanilli, Dan G Duda, John R Fike, Dolores Hambardzumyan, Richard P Hill, Craig T Jordan, Luka Milas, Frank Pajonk, Walter J Curran, Adam P Dicker, Yuhchyau Chen. Int J Radiat Oncol Biol Phys 2009(Aug 1); 74(5): 1580-91 [Epub 2009(Jun 17)]. PubMed Abstract:
At a meeting of the Translation Research Program of the Radiation Therapy Oncology Group held in early 2008, attendees focused on updating the current state of knowledge in cancer stem cell research and discussing ways in which this knowledge can be translated into clinical use across all disease sites. This report summarizes the major topics discussed and the future directions that research should take. Major conclusions of the symposium were that the flow cytometry of multiple markers in fresh tissue would remain the standard technique of evaluating cancer-initiating cells and that surrogates need to be developed for both experimental and clinical use.

Wednesday, July 22, 2009

CD133 expression has high prognostic impact for colon cancer

The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer by David Horst and 6 co-authors, including Thomas Kirchner and Andreas Jung, J Pathol 2009(Jun 25) [Epub ahead of print] PubMed Abstract:
In colon cancer, CD133 has recently been used to enrich for a subset of tumour cells with tumour-initiating capabilities and was therefore suggested to mark colon cancer stem cells. However, this molecule has surprisingly been shown to lack functional importance for tumour initiation itself. Herein, we investigated whether CD133 may be relevant for colon cancer metastasis in patients, and as metastasis requires several additional biological characteristics besides tumour initiation, we examined the effects of knocking down CD133 expression in colon cancer cell lines on proliferation, migration, invasion, and colony formation. We demonstrate that high CD133 expression correlates strongly with synchronous liver metastasis in a matched case-control collection, while siRNA-mediated knock down of this factor has no significant effect on the mentioned biological characteristics. Thus, we conclude that CD133 expression is a marker with high prognostic impact for colon cancer, while it seems to have no obvious functional role as a driving force of this malignancy.

Video from Stanford about CSC

Cancer Stem Cells: The Origin of Cancer. Video (Runtime: 00:48:26) produced by Stanford University Medical Center, February 11, 2009. Description:
Irving Weissman, professor of developmental biology at Stanford University Medical Center, addresses what cancer stem cells are, how they maintain themselves and why they may be resistant to some current treatments. Weissman also talks about the "don't eat me" signal and how it relates to the growth of certain types of cancer cells. Find out how Stanford scientists and clinicians are working to identifying cancer stem cells in many types of tumors and how they have used that information to develop new therapeutic strategies.
Comment: Captions are available for this video. If viewed using QuickTime, the captions will be visible when the video is launched. (Unfortunately, the captions haven't been copyedited by the speaker, and contain some errors).

Saturday, July 18, 2009

Alloreactive NK cells detect and target leukemic SCs

Human acute myeloid leukemia CD34+CD38– stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells by Ulrich Langenkamp and 6 co-authors, including Aleksandra Wodnar-Filipowicz, Haematologica 2009(Jul 16) [Epub ahead of print][FriendFeed entry][Early version of the full text PDF]. PubMed Abstract:
The concept of tumor immunosurveillance has raised prospects for natural killer (NK) cell-based immunotherapy of human cancer. The cure of acute myeloid leukemia (AML) may depend on eradication of leukemic stem cells (LSCs), the self-renewing component of leukemia. Whether NK cells can recognize and lyse LSCs is not known. To develop strategies that effectively target AML-LSCs, we investigated anti-leukemic effects of human alloreactive single KIR(+) NK cells. NK effectors with KIR specificity mismatched with respect to HLA class I allotype of target cells effectively recognized AML-LSCs defined phenotypically as CD34(+)CD38(-), while healthy bone marrow-derived CD34(+)CD38(-) hematopoietic stem cells were spared, as demonstrated by cytotoxicity and hematopoietic colony-forming assays. The HDAC inhibitor valproic acid augmented the activating NKG2D ligand-dependent lysis of AML-CD34(+)CD38(-) LSCs. These results show that alloreactive NK cells have the potential to detect and target LSCs, and thus to improve the treatment outcome in AML.

Chemosensitization of AML

Another nail in the AML coffin by Camille N Abboud, Blood 2009(Jun 11); 113(24): 6045-6. Editorial [Full text is currently publicly accessible][PubMed Citation]. First paragraph:
In this issue of Blood, Nervi and colleagues and Zeng and colleagues independently report similar findings in both in vitro and in vivo AML models, showing chemosensitization by blocking CXCR4/CXCL12 (SDF-1{alpha}:stromal cell–derived factor 1) signaling using novel CXCR4 antagonist bicyclams, namely AMD3100 (plerixafor) and AMD3465.
Excerpt from the final paragraph:
Finally, while both reports open new avenues for overcoming in vivo drug resistance in AML, it is yet unclear whether durable complete remissions can ensue from this strategy. AML is indeed a very heterogenous disease, and successful eradication of leukemic stem/progenitor cells will require blocking multiple receptors/pathways ...
The two articles discussed in this editorial are:

1) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 by Bruno Nervi and 10 co-authors, including Timothy J Ley, and John F DiPersio, Blood 2009(Jun 11); 113(24): 6206-14 [Epub 2008(Dec 2)]. [PubMed Citation].

2) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML by Zhihong Zeng and 12 co-authors, Blood 2009(Jun 11); 113(24): 6215-24 [Epub 2008(Oct 27)]. [PubMed Citation][FriendFeed entry].

[Only the abstracts of these two articles are currently publicly accessible].

Friday, July 17, 2009

Partnership to develop new colon cancer drugs

Ontario joins top researchers, Pfizer, to develop new colon cancer drugs by Amy Fuller, Canadian Press (via Winnipeg Free Press), July 15, 2009. (See also the same news release, via Yahoo News). First two paragraphs:
The fight against colon cancer got an infusion of funds Wednesday as the Ontario government and leading medical research centres joined with the world's largest pharmaceutical research company to develop new drugs.
Pfizer, a New York-based company with 1,400 employees across Canada, is partnering with the Ontario Cancer Institute and the Ontario Institute for Cancer Research in a $6.9-million collaboration over three years.
See also: Pfizer Gives $5.4M for Ontario Cancer Research Project, GenomeWeb Daily News, July 16, 2009. [Free registration required][Twitter entry]. Excerpts:
Pfizer Global Research and Development will collaborate with two Ontario institutes to discover and validate targets that could be used to diagnose, predict, or treat colorectal cancer.
.....
Ben Neel, who is director of OCI and is serving as a principal investigator on the project, said in a statement that the collaboration will "join the world class genomics and informatics programs at OICR, cutting edge research in cancer stem cell biology and functional genomics at OCI/PMH and the world's largest pharmaceutical company in a concerted effort to bring new therapies to colon cancer patients worldwide."